Active	Status	Sponsor type	Region	Phase	Filter
4 Active 1 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
GEN-001 / Genome & Company
GEN001-201, NCT05419362: GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer	Active, not recruiting	2	42	RoW	GEN-001, Avelumab, Bavencio	Genome & Company, Merck KGaA, Darmstadt, Germany	Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	12/24	12/24
KEYNOTE-D86, NCT05998447: GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer	Recruiting	2	148	RoW	GEN-001, Pembrolizumab, KEYTRUDA®, mFOLFOX	Genome & Company, Merck Sharp & Dohme LLC	Biliary Tract Cancer	10/26	10/26
NCT04601402: GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy	Completed	1	11	US	GEN-001, Avelumab, Bavencio	Genome & Company, Merck KGaA, Darmstadt, Germany, Pfizer	Solid Tumor, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma	01/23	01/23
NCT05079503: Gut Microbiome and Its Immune Modulation in Locally Advanced Rectal Cancer	Not yet recruiting	N/A	40	NA	GEN-001, Lactococcus lactis	Korean Cancer Study Group	Locally Advanced Rectal Cancer	08/23	01/24
lactobacillus reuteri (SB-121) / Scioto Biosci, Genome & Company
No trials found
GENA-104 / Genome & Company
No trials found
GENA-105 / Genome & Company
No trials found
GEN-501 / Genome & Company
No trials found
GENA-111-AF / Debiopharm
No trials found